<DOC>
	<DOCNO>NCT02236026</DOCNO>
	<brief_summary>The purpose study evaluate effect Nestorone ( NES ) administer bolus injection correct QT interval use Fridericia 's formula ( QTcF ) .</brief_summary>
	<brief_title>A Study With Open-Label Active Control Evaluate Potential Nestorone® Delay Cardiac Repolarization Healthy Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>ST 1435</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Is premenopausal female , ≥ 18 &lt; 40 year age time Screening ; Has BMI ≥ 18.5 ≤ 32 kg/m2 ( weight ≥ 50 kg ) Screening Is state general good health base medical history physical examination ; Is regularly menstruate ( cycle 22 35 day duration ) previous 6 month prior Screening , report subject ; If childbearing potential , must practice acceptable nonhormonal , method birth control end study ( Exit/Early Termination ) . Such method include limited : Sexual abstinence ; Male female condom combination spermicidal foam/gel/cream/ suppository ; Vasectomized female partner ; Diaphragm/cervical cap spermicide ; Bilateral tubal ligation sterilization least 6 month screen visit , ESSURE ADIANA procedure hysterosalpingography confirmation test least 6 month screen visit ; Copper intrauterine device . Is able fulfill requirement protocol , indicate willingness participate study provide write informed consent authorization disclose PHI . Is pregnant lactating ; Has hypersensitivity allergy NES , moxifloxacin , related compound , inactive ingredient use investigational product formulation ; Has contraindication progestin estrogen therapy ; Has impair hypothalamicpituitaryadrenal reserve , history oral glucocorticoid replacement therapy 12 month prior Screening . Has experience undiagnosed genital bleeding , exclude intermenstrual spotting , within 6 month Screening ; Has undergone gynecological examination , result clinically significant abnormality , Screening ; Has treatment oral , topical vaginal steroid hormone ( e.g. , estrogens , progestogen , androgen [ include dehydroepiandrosterone ] , corticosteroid ) within 8 week prior Screening , treatment injectable implantable steroid time 6 month prior Screening ; Is currently use , use within 6 month prior Screening , hormonal contraception progestin intrauterine device . Has know suspect carcinoma breast ; Has benign malignant liver tumor acute liver disease ; Has current past thrombophlebitis thromboembolic disorder family history thromboembolic disorder ; Has personal history myocardial disease , Long QT Syndrome personal family history Long QT Syndrome ( e.g. , AndersonTawil Syndrome [ micrognathia , low set ear , clinodactyly ] ; Timothy 's Syndrome [ syndactyly autism spectrum disorder ] ; : Jervell/LangeNielsen Syndrome [ bilateral hearing loss ] ; RomanoWard Syndrome [ fainting , seizures ] ) , unexplained syncope presyncope , current recurrent hypokalemia . Has family history genetically related grandparent , parent , uncles/aunts , cousin , child Long QT Syndrome , nonischemic cardiomyopathy , unexplained sudden death 50 year age . Has abnormal 12lead ECG , clinically significant abnormality rate , rhythm , conduction include : HR &lt; 45 &gt; 90 beat per minute ( bpm ) , 5 minute supine rest ; PR interval &gt; 220 m ; QRS interval &gt; 120 m ; QTcF correct QT interval use Bazett 's formula ( determined Investigator ) &gt; 450 m ; QTcF &lt; 300 m ; Any degree clinically significant fascicular block , bundle branch block , intraventricular conduction delay ; QRS and/or T wave Investigator judge unfavorable consistently accurate QT measurement ( e.g. , indistinct QRS onset , low amplitude T wave , invert terminally inverted T wave , merge T/U wave , indistinct T wave offset , prominent U wave affect QT measurement ) ; Neuromuscular artifact readily eliminate ; Has , ECG , premature atrial ventricular beat find Investigator 's opinion represent clinically significant excessive HR variation ; Has clinically significant deviation normal screening test initial exam , opinion Investigator , might present safety risk participation would confound analysis interpretation study result ; Has participate clinical study use investigational drug within 60 day prior Screening ; Requires use medication , include overthecounter product , nutritional supplement , exception aspirin , ibuprofen , acetaminophen . Medications exclusionary discontinue describe ; however , circumstance medication discontinue would place subject risk ; Medications ( include nutritional supplement ) know moderate potent inhibitor cytochrome P450 ( CYP ) 3A4 , prolong QT/QTc interval , must discontinue least 21 day prior study entry ( Day 1 Treatment Period 1 ) ; All prescription medication must discontinue least 14 day prior study entry ( Day 1 Treatment Period 1 ) , unless opinion Investigator concomitant use medication place subject risk confound collection , analysis , interpretation study data ; Overthecounter medication ( include nutritional supplement ) must discontinue least 7 day prior study entry ( Day 1 Treatment Period 1 ) ; Foods beverage contain alcohol , caffeine , xanthine , grapefruit allow within 48 hour Day 1 treatment period . Has positive hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) screen ; Has positive test alcohol drug abuse , history know suspected alcohol drug abuse ; Has use tobacco product within 6 month prior Screening , positive urine test tobacco use ; Has donate 400 mL blood/plasma 60 day prior Day 1 Treatment Period 1 ; Is unable unwilling provide write informed consent comply activity instruction study ; Is judge Investigator unsuitable reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Nestorone use IV solution heart rate ;</keyword>
	<keyword>Abnormality Heart Rate Rhythm , Unspecified Time Onset</keyword>
</DOC>